Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NYSE:ANRO NASDAQ:ENLV NASDAQ:ESPR NASDAQ:VOR On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeANROAlto Neuroscience$24.53+1.9%$22.78$2.15▼$28.44$783.00M1.62269,121 shs43,096 shsENLVEnlivex Therapeutics$0.78-2.5%$0.99$0.66▼$2.10$186.11M1.49522,246 shs91,367 shsESPREsperion Therapeutics$3.15+0.2%$2.53$0.69▼$4.18$809.54M0.918.57 million shs2.60 million shsVORVor Biopharma$16.99+5.6%$15.05$2.62▼$65.80$918.67M1.75987,951 shs198,531 shsOptions Trading Made Easy - Download NowLearn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceANROAlto Neuroscience-2.29%-7.19%+12.62%+55.57%+1,002.03%ENLVEnlivex Therapeutics-3.96%-2.42%-4.01%-31.03%-23.81%ESPREsperion Therapeutics-0.32%+57.00%+35.93%-7.65%+260.92%VORVor Biopharma+1.13%+12.21%-4.57%+22.19%+1,607,999,900.00%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeANROAlto Neuroscience$24.53+1.9%$22.78$2.15▼$28.44$783.00M1.62269,121 shs43,096 shsENLVEnlivex Therapeutics$0.78-2.5%$0.99$0.66▼$2.10$186.11M1.49522,246 shs91,367 shsESPREsperion Therapeutics$3.15+0.2%$2.53$0.69▼$4.18$809.54M0.918.57 million shs2.60 million shsVORVor Biopharma$16.99+5.6%$15.05$2.62▼$65.80$918.67M1.75987,951 shs198,531 shsOptions Trading Made Easy - Download NowLearn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceANROAlto Neuroscience-2.29%-7.19%+12.62%+55.57%+1,002.03%ENLVEnlivex Therapeutics-3.96%-2.42%-4.01%-31.03%-23.81%ESPREsperion Therapeutics-0.32%+57.00%+35.93%-7.65%+260.92%VORVor Biopharma+1.13%+12.21%-4.57%+22.19%+1,607,999,900.00%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceANROAlto Neuroscience 2.67Moderate Buy$35.1343.19% UpsideENLVEnlivex Therapeutics 2.00Hold$16.502,007.28% UpsideESPREsperion Therapeutics 2.00Hold$5.5476.15% UpsideVORVor Biopharma 2.75Moderate Buy$50.56197.65% UpsideCurrent Analyst Ratings BreakdownLatest ENLV, ANRO, ESPR, and VOR Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/5/2026ANROAlto Neuroscience Bank of AmericaSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$35.005/4/2026ESPREsperion Therapeutics Needham & Company LLCSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeBuy ➝ Hold5/1/2026ANROAlto Neuroscience Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeSell (E+) ➝ Sell (D-)5/1/2026ESPREsperion Therapeutics Jefferies Financial GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeStrong-Buy ➝ Hold5/1/2026ESPREsperion Therapeutics Citizens JmpSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeStrong-Buy ➝ Hold5/1/2026ESPREsperion Therapeutics Piper SandlerSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeStrong-Buy ➝ Hold5/1/2026ESPREsperion Therapeutics Cantor FitzgeraldSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeStrong-Buy ➝ Hold5/1/2026ESPREsperion Therapeutics HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeBuy ➝ Neutral$3.164/30/2026VORVor Biopharma Jefferies Financial GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong-Buy4/22/2026ANROAlto Neuroscience Chardan CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$30.004/21/2026ESPREsperion Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)(Data available from 5/8/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookANROAlto NeuroscienceN/AN/AN/AN/A$4.87 per shareN/AENLVEnlivex TherapeuticsN/AN/AN/AN/A$8.15 per shareN/AESPREsperion Therapeutics$403.14M2.01N/AN/A($1.26) per share-2.50VORVor BiopharmaN/AN/AN/AN/AN/AN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateANROAlto Neuroscience-$63.24M-$2.18N/AN/AN/AN/A-47.64%-37.83%5/13/2026 (Estimated)ENLVEnlivex Therapeutics$1.24B-$0.55N/AN/AN/AN/A248.08%206.39%N/AESPREsperion Therapeutics-$22.68M-$0.17N/A14.302.56-3.66%N/A-3.93%N/AVORVor BiopharmaN/A-$386.83N/AN/AN/AN/AN/AN/AN/ALatest ENLV, ANRO, ESPR, and VOR EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/13/2026Q1 2026ANROAlto Neuroscience-$0.56N/AN/AN/AN/AN/A3/16/2026Q4 2025ANROAlto Neuroscience-$0.56-$0.45+$0.11-$0.45N/AN/A3/10/2026Q4 2025ESPREsperion Therapeutics$0.23$0.22-$0.01$0.22$165.12 million$168.45 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthANROAlto NeuroscienceN/AN/AN/AN/AN/AENLVEnlivex TherapeuticsN/AN/AN/AN/AN/AESPREsperion TherapeuticsN/AN/AN/AN/AN/AVORVor BiopharmaN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioANROAlto Neuroscience0.1215.6915.69ENLVEnlivex TherapeuticsN/A193.24193.24ESPREsperion TherapeuticsN/A1.541.19VORVor BiopharmaN/AN/AN/ACompare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipANROAlto NeuroscienceN/AENLVEnlivex Therapeutics1.02%ESPREsperion Therapeutics47.39%VORVor Biopharma97.29%Insider OwnershipCompanyInsider OwnershipANROAlto Neuroscience11.25%ENLVEnlivex Therapeutics12.28%ESPREsperion Therapeutics1.70%VORVor Biopharma0.45%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableANROAlto NeuroscienceN/A31.95 million28.35 millionN/AENLVEnlivex Therapeutics70237.38 million208.23 millionOptionableESPREsperion Therapeutics200257.41 million253.03 millionOptionableVORVor Biopharma14054.19 million53.94 millionN/AENLV, ANRO, ESPR, and VOR HeadlinesRecent News About These CompaniesWall Street Analysts Believe Vor Biopharma (VOR) Could Rally 124.59%: Here's is How to TradeMay 7 at 10:55 AM | zacks.comVor Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)May 4, 2026 | globenewswire.comVor Biopharma (NASDAQ:VOR) Stock Rating Upgraded by Jefferies Financial GroupMay 2, 2026 | americanbankingnews.comJefferies Financial Group Upgrades Vor Biopharma (NASDAQ:VOR) to Strong-BuyMay 1, 2026 | marketbeat.comVor Biopharma Inc. (NASDAQ:VOR) Receives Consensus Rating of "Moderate Buy" from BrokeragesMay 1, 2026 | marketbeat.comVor Biopharma Inc. (NASDAQ:VOR) Short Interest Down 17.3% in AprilApril 30, 2026 | marketbeat.comVor Biopharma (NASDAQ:VOR) Director Ra Capital Management, L.P. Sells 165,150 SharesApril 24, 2026 | marketbeat.comVor Biopharma (NASDAQ:VOR) Director Sells $2,711,856.51 in StockApril 22, 2026 | insidertrades.comInsider Selling: Vor Biopharma (NASDAQ:VOR) Director Sells 171,963 Shares of StockApril 21, 2026 | marketbeat.comVor Biopharma (NASDAQ:VOR) Director Sells $7,462,931.08 in StockApril 21, 2026 | marketbeat.comVor Biopharma (NASDAQ:VOR) Shares Down 4.4% - Here's What HappenedApril 20, 2026 | marketbeat.comDoes Vor Biopharma (VOR) Have the Potential to Rally 117% as Wall Street Analysts Expect?April 20, 2026 | zacks.comVor Biopharma (NASDAQ:VOR) Trading 9.7% Higher - What's Next?April 17, 2026 | marketbeat.comVor Biopharma Q1 EPS Estimate Increased by HC WainwrightApril 17, 2026 | marketbeat.comRa Capital Management, L.P. Sells 53,644 Shares of Vor Biopharma (NASDAQ:VOR) StockApril 16, 2026 | insidertrades.comRa Capital Management, L.P. Sells 530,610 Shares of Vor Biopharma (NASDAQ:VOR) StockApril 15, 2026 | marketbeat.comVor Biopharma (NASDAQ:VOR) Director Sells $858,840.44 in StockApril 15, 2026 | marketbeat.comInsider Selling: Vor Biopharma (NASDAQ:VOR) Director Sells 153,735 Shares of StockApril 15, 2026 | marketbeat.comHC Wainwright Has Lowered Expectations for Vor Biopharma (NASDAQ:VOR) Stock PriceApril 15, 2026 | marketbeat.comVor Biopharma Inc. (NASDAQ:VOR) Short Interest Up 66.5% in MarchApril 13, 2026 | marketbeat.comRa Capital Management, L.P. Sells 828 Shares of Vor Biopharma (NASDAQ:VOR) StockApril 11, 2026 | insidertrades.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeENLV, ANRO, ESPR, and VOR Company DescriptionsAlto Neuroscience NYSE:ANRO$24.53 +0.46 (+1.91%) As of 11:33 AM Eastern This is a fair market value price provided by Massive. Learn more.Alto Neuroscience, Inc. operates as a clinical-stage biopharmaceutical company in the United States. Its product pipeline comprising ALTO-100, which is in phase 2b clinical trial for the treatment of patients with major depressive disorder (MDD); and which is in phase 2a clinical trial for the treatment of post-traumatic stress disorder. The company develops ALTO-300, a small molecule melatonergic agonist and serotonergic antagonist with antidepressant properties which is in phase 2b clinical trial to treat patients with MDD; ALTO-101, a novel small molecule phosphodiesterase 4 inhibitor which is in phase 1 clinical trial for the treatment of cognitive impairment associated with schizophrenia; ALTO-203, a novel small-molecule histamine H3 receptor inverse agonist which is in phase 1 clinical trial to treat patients with MDD and higher levels of anhedonia; and ALTO-202, an investigational orally bioavailable antagonist of the GluN2B subunit of the NMDA receptor which is in phase 1 clinical trial for the treatment of MDD. In addition, it develops novel pharmacodynamically synergistic combination and biomarker platform that collects patient-specific data to identify biomarker-characterized patient. The company was incorporated in 2019 and is headquartered in Los Altos, California.Enlivex Therapeutics NASDAQ:ENLV$0.78 -0.02 (-2.50%) As of 11:32 AM Eastern This is a fair market value price provided by Massive. Learn more.Enlivex Therapeutics Ltd., together with its subsidiaries, operates as a clinical-stage macrophage reprogramming immunotherapy company in Israel. Its product pipeline is the Allocetra, which is in phase II clinical trial for the treatment of organ dysfunction caused by sepsis. The company also develops Allocetra for the treatment of moderate knee osteoarthritis and end-stage knee osteoarthritis which is in phase I/II clinical trial. Enlivex Therapeutics Ltd. is headquartered in Ness Ziona, Israel.Esperion Therapeutics NASDAQ:ESPR$3.14 +0.01 (+0.16%) As of 11:34 AM Eastern This is a fair market value price provided by Massive. Learn more.Esperion Therapeutics, Inc., a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol (LDL-C). Its marketed products include NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets that are oral, once-daily, non-statin medicines for the treatment of primary hyperlipidemia in adults with heterozygous familial hypercholesterolemia or atherosclerotic cardiovascular disease who require additional lowering of LDL-C. The company's products also include NILEMDO, an ATP Citrate Lyase (ACL) inhibitor that lowers LDL-C and cardiovascular risk by reducing cholesterol biosynthesis and up-regulating the LDL receptors; and NUSTENDI, a bempedoic acid and ezetimibe tablet to treat elevated LDL-C. The company has license and collaboration agreements with Daiichi Sankyo Co. Ltd to; Otsuka Pharmaceutical Co., Ltd; and Daiichi Sankyo Europe GmbH. Esperion Therapeutics, Inc. was incorporated in 2008 and is headquartered in Ann Arbor, Michigan.Vor Biopharma NASDAQ:VOR$16.98 +0.91 (+5.63%) As of 11:34 AM Eastern This is a fair market value price provided by Massive. Learn more.Vor Biopharma, Inc., a clinical-stage company, develops engineered hematopoietic stem cell (eHSC) therapies for cancer patients. It is developing VOR33, an eHSC product candidate that is in phase 1/2 to treat acute myeloid leukemia (AML) and other hematological malignancies. The company's VOR33 eHSCs lacks CD33, a protein that is expressed by AML blood cancer cells. The company's eHSCs targeted therapies, such as CAR-Ts, bispecific antibodies, and antibody-drug conjugates provide treatment for blood cancers. Vor Biopharma, Inc. has a collaboration agreement with Akron BioProducts to develop and manufacture cGMP nucleases. The company was incorporated in 2015 and is headquartered in Cambridge, Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Dutch Bros Q1 Earnings: The Newest Starbucks Rival Faces Its First Big Reality Check The AI Fear Around Datadog Stock May Have Been Completely Wrong Amprius Technologies Ups the Voltage on Forward Outlook Why Lam Research Still Looks Like a Buy After a 300% Rally Wells Fargo’s Comeback Is Real—But Not Risk-Free IonQ Just Posted a Breakout Quarter—But 1 Problem Remains SLB’s Tough Quarter Masks a Powerful Long-Term Shift Super Micro Surges Over 20% as Margins Soar, Sales Fall Short Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
